Apyx Medical Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.36%.
Did APYX Beat Earnings? Q2 2025 Results
Apyx Medical delivered a mixed but pivotal second quarter, matching the Wall Street consensus on earnings while falling just short on revenue, as the company's most consequential product launch in years stole the spotlight from the headline numbers. Revenue declined 6.4% year over year to $11.37 million, missing the $11.70 million consensus estimate by 2.79%, with a 28.5% drop in OEM segment sales dragging on total results even as the core Advanced Energy business held relatively steady. The company lost $0.09 per share, in line with estimates, while the net loss narrowed sharply to $3.78 million from $6.56 million a year ago, reflecting aggressive cost discipline that trimmed total operating expenses by $3.40 million. The real story, however, was the FDA clearance and soft launch of the AYON Body Contouring System, which drew stronger-than-expected early surgeon interest and prompted management to raise full-year 2025 revenue guidance to $50.00 million to $52.00 million, up from a prior range of $47.60 million to $49.00 million, with a nationwide rollout planned for September.
- Advanced Energy segment revenue relatively flat year-over-year at $9.7 million
- Gross margin improved to 62.3% from 61.7% due to favorable product mix shift toward Advanced Energy
- Operating expenses decreased $3.4 million driven by reductions in salaries, SG&A, R&D, and professional services
- Net loss narrowed by 42% year-over-year to $3.8 million
- Adjusted EBITDA loss improved 54% to $2.0 million
“Building on the growing success of Renuvion in the U.S., we recently initiated the soft commercial launch of the AYON following FDA clearance in the second quarter of 2025. Customer interest in AYON quickly exceeded our expectations for this early stage of the rollout, with surgeons selected to be early adopters already installing our system and performing initial procedures. As a result, we have increased our revenue guidance for the full year 2025 to $50.0 million to $52.0 million and look forward to a nationwide launch of AYON in September.”
Apyx Medical CEO, on the earnings call
Forward Guidance & Outlook
Apyx Medical raised its full-year 2025 revenue guidance to $50.0 million to $52.0 million, up from previous guidance of $47.6 million to $49.0 million, driven by stronger-than-expected early demand for the AYON Body Contouring System. Advanced Energy revenue is now expected to be $42.0 million to $44.0 million (up from $39.6 million to $41.0 million). OEM revenue is expected to be approximately $8.0 million. Total operating expenses are expected to be less than $40.0 million for the full year. The company plans a nationwide commercial launch of AYON in September 2025.
APYX YoY Financials
APYX Revenue by Segment
APYX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.